Holding(s) in Company
January 26 2009 - 6:14AM
UK Regulatory
TIDMHIK TIDMLGEN
RNS Number : 2343M
Hikma Pharmaceuticals Plc
26 January 2009
Notification of major interests in shares
LONDON, 26 January 2009 - Hikma Pharmaceuticals PLC ("Hikma") (LSE: HIK) (DIFX:
HIK), the fast growing multinational pharmaceuticals group, announces as
follows:
+---------------------------+------------------------------------------------------------------------------------------------------------+---------------------------+
| 1 | Identity of the issuer or the underlying issuer of existing shares to which the voting rights are attached | Hikma Pharmaceuticals PLC |
| | | |
+---------------------------+------------------------------------------------------------------------------------------------------------+---------------------------+
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
| 2 | Reason for the notification | Yes/no |
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
| | An acquisition or disposal of voting rights | Yes |
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
| | An acquisition or disposal of financial instruments which may result in the acquisition of shares already issues to which voting rights are attached | |
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
| | An event changing the breakdown of voting rights | |
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
| | Other (please specify): Compliance with the Transparency Directive | |
+---------------------------+------------------------------------------------------------------------------------------------------------------------------------------------------+---------------------------+
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 3 | Full name of the person subject to the notification obligation | Legal & General Group Plc (L&G) |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 4 | Full name of shareholders if different from above | - |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 5 | Date of the Transaction (and date on which the threshold crossed is reached differently) | 22 January 2009 |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 6 | Date on which the issuer notified | 23 January 2009 |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 7 | Threshold that is crossed | Below 3% (L&G) |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
| 8 | Notified details: | |
+---------------------------+------------------------------------------------------------------------------------------+---------------------------------+
+--------------------------------------------------------+------------------+-------------------------+---------+----------+---------+----------+---------+----------+
| A. Voting rights attached to shares |
+--------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Class type of shares (if possible using the ISIN code) | Situation | Resulting situation after the triggering transaction |
| | previous to the | |
| | triggering | |
| | transaction | |
+ +--------------------------------------------+--------------------------------------------------------------+
| | Number of shares | Number of voting rights | Number of shares | Number of voting | % of voting |
| | | | | rights | rights |
+ + + +--------------------+--------------------+--------------------+
| | | | Direct | Indirect | Direct | Indirect | Direct | Indirect |
+--------------------------------------------------------+------------------+-------------------------+---------+----------+---------+----------+---------+----------+
| Ordinary Shares (0.10 GBP) | 5,181,598 | 5,181,598 | Below 3% |
+--------------------------------------------------------+------------------+-------------------------+---------+----------+---------+----------+---------+----------+
+------------------------------+-----------------+---------------------------------+---------------------------------------------------------------------------------------+--------------------+
| B. Financial instruments |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Resulting situation after the triggering transaction |
+-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------+
| Type of financial instrument | Expiration Date | Exercise/Conversion Period/Date | Number of voting rights that may be acquired if the instrument if exercised/converted | % of voting rights |
+------------------------------+-----------------+---------------------------------+---------------------------------------------------------------------------------------+--------------------+
| | | | | |
+------------------------------+-----------------+---------------------------------+---------------------------------------------------------------------------------------+--------------------+
+----------------------------------------+----------------------------------------+
| Total A+B |
+---------------------------------------------------------------------------------+
| Number of Voting rights | % of voting rights |
+----------------------------------------+----------------------------------------+
| Below 3% |
+----------------------------------------+----------------------------------------+
+----------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+
| 9 | Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable |
+----------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+
| | Legal & General Group Plc (Direct and Indirect) |
| | (Group) |
| | Legal & General Investment Management (Holdings) |
| | Limited (LGIMH) (Direct and Indirect) |
| | Legal & General Investment Management Limited |
| | (Indirect) (LGIM) |
| | Legal & General Group Plc (Direct) (L&G) (Below 3% = LGAS, LGPL & PMC) |
| | Legal & General Investment Management (Holdings) Limited (Direct) (LGIMHD) Legal & General Insurance Holdings Limited (Direct) |
| | (LGIH) |
| | Legal & General Assurance (Pensions Management) Limited (PMC) Legal & General Assurance Society Limited (LGAS & |
| | LGPL) |
| | Legal & General Pensions Limited (Direct) (LGPL) |
| | |
+----------------------------------------+---------------------------------------------------------------------------------------------------------------------------------------+
+---------------------------+-------------------------------------------------------------+---------------------------+
| Proxy Voting | |
+-----------------------------------------------------------------------------------------+---------------------------+
| 10 | Name of the proxy holder | N/A |
+---------------------------+-------------------------------------------------------------+---------------------------+
| 11 | Number of voting rights proxy holder will cease to hold | N/A |
+---------------------------+-------------------------------------------------------------+---------------------------+
| 12 | Date on which proxy holder will cease to hold voting rights | N/A |
+---------------------------+-------------------------------------------------------------+---------------------------+
+---------------------------+---------------------------+-------------------------------------------------------------------+
| 13 | Additional Information | Notification using the total voting rights figure of 189,237,607 |
| | | |
+---------------------------+---------------------------+-------------------------------------------------------------------+
- ENDS -
Enquiries:
+----------------------------------------+----------------------------------------+
| Hikma Pharmaceuticals PLC | |
+----------------------------------------+----------------------------------------+
| Henry Knowles | +44 20 7399 2760 |
| Company Secretary | |
| | |
+----------------------------------------+----------------------------------------+
About Hikma
Hikma Pharmaceuticals PLC is a fast growing multinational group focused on
developing, manufacturing and marketing a broad range of both branded and
non-branded generic and in-licensed products. Hikma operates through three
businesses: "Branded", "Injectables" and "Generics", based principally in the
Middle East and North Africa ("MENA"), where it is a market leader and sells
across 17 countries, the United States and Europe. In 2007, Hikma achieved
revenues of $449 million and profit attributable to shareholders of $63 million.
At 31 December 2007, the Group had over 3,000 employees. For news and other
information, please visit www.hikma.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUNAARKARAUAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
